Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Center, Proof of Concept, Phase 2B, Randomized, Double-Blind, Study to Assess the Efficacy, Safety, and Tolerability of ALLOD-2 vs. Placebo in the Prevention of Episodic Migraine in Adults (ANODYNE-3)

Trial Profile

A Single Center, Proof of Concept, Phase 2B, Randomized, Double-Blind, Study to Assess the Efficacy, Safety, and Tolerability of ALLOD-2 vs. Placebo in the Prevention of Episodic Migraine in Adults (ANODYNE-3)

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 20 Apr 2018

At a glance

  • Drugs ALLOD 2 (Primary)
  • Indications Migraine with aura; Migraine without aura
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ANODYNE-3
  • Sponsors Allodynic Therapeutics
  • Most Recent Events

    • 14 Apr 2018 Status changed from recruiting to active, no longer recruiting.
    • 29 Oct 2017 Planned number of patients changed from 48 to 12.
    • 04 Aug 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top